Cyrus Rustam Mehta, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sample Size | 17 | 2017 | 845 | 2.460 |
Why?
|
| Research Design | 21 | 2017 | 6209 | 1.930 |
Why?
|
| Data Interpretation, Statistical | 14 | 2014 | 2686 | 1.700 |
Why?
|
| Clinical Trials as Topic | 19 | 2017 | 8041 | 1.550 |
Why?
|
| Uracil | 10 | 2018 | 210 | 1.150 |
Why?
|
| Confidence Intervals | 9 | 2016 | 2910 | 1.030 |
Why?
|
| Models, Statistical | 19 | 2017 | 5089 | 1.010 |
Why?
|
| Biometry | 11 | 2017 | 571 | 0.830 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2016 | 878 | 0.750 |
Why?
|
| Piperidines | 10 | 2018 | 1664 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2014 | 10383 | 0.600 |
Why?
|
| Acute Coronary Syndrome | 10 | 2018 | 2184 | 0.500 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 553 | 0.470 |
Why?
|
| Endpoint Determination | 5 | 2017 | 591 | 0.440 |
Why?
|
| Markov Chains | 2 | 2014 | 968 | 0.400 |
Why?
|
| Femur | 1 | 2018 | 1310 | 0.380 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2018 | 318 | 0.370 |
Why?
|
| Epidemiologic Research Design | 2 | 2010 | 368 | 0.340 |
Why?
|
| Computer Simulation | 10 | 2017 | 6255 | 0.320 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 1416 | 0.290 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 1731 | 0.280 |
Why?
|
| Hypoglycemic Agents | 9 | 2017 | 3110 | 0.280 |
Why?
|
| Algorithms | 11 | 2017 | 14071 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2018 | 12240 | 0.240 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2017 | 85 | 0.240 |
Why?
|
| Neurotoxins | 1 | 2004 | 238 | 0.210 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 1727 | 0.190 |
Why?
|
| Diabetic Angiopathies | 3 | 2017 | 805 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2016 | 639 | 0.180 |
Why?
|
| Standard of Care | 3 | 2017 | 567 | 0.150 |
Why?
|
| Gatekeeping | 1 | 2017 | 49 | 0.140 |
Why?
|
| Likelihood Functions | 3 | 2001 | 993 | 0.130 |
Why?
|
| Myocardial Revascularization | 2 | 2017 | 793 | 0.120 |
Why?
|
| Monte Carlo Method | 3 | 2013 | 1238 | 0.120 |
Why?
|
| Humans | 48 | 2018 | 765968 | 0.120 |
Why?
|
| Acetabulum | 1 | 2018 | 543 | 0.110 |
Why?
|
| Probability | 5 | 1994 | 2475 | 0.110 |
Why?
|
| Naphthyridines | 1 | 2015 | 182 | 0.110 |
Why?
|
| Cytarabine | 1 | 2015 | 698 | 0.110 |
Why?
|
| Propranolol | 1 | 2015 | 492 | 0.110 |
Why?
|
| Angina, Unstable | 2 | 2015 | 893 | 0.100 |
Why?
|
| Glucosides | 1 | 2017 | 531 | 0.100 |
Why?
|
| Troponin I | 1 | 2017 | 655 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2013 | 68 | 0.100 |
Why?
|
| Deep Brain Stimulation | 2 | 2013 | 850 | 0.100 |
Why?
|
| Government Regulation | 1 | 2016 | 525 | 0.100 |
Why?
|
| Double-Blind Method | 8 | 2017 | 12437 | 0.090 |
Why?
|
| Hip Joint | 1 | 2018 | 1000 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 939 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 10729 | 0.090 |
Why?
|
| Hemangioma | 1 | 2015 | 723 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2017 | 896 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1514 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1237 | 0.080 |
Why?
|
| Myocardial Infarction | 5 | 2018 | 11499 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1393 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 2393 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 1994 | 2844 | 0.070 |
Why?
|
| Thiazoles | 1 | 2015 | 1529 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2014 | 10070 | 0.070 |
Why?
|
| Treatment Outcome | 11 | 2018 | 65188 | 0.070 |
Why?
|
| Parkinson Disease | 2 | 2013 | 2895 | 0.070 |
Why?
|
| Software | 2 | 2006 | 4462 | 0.070 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 15652 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 3850 | 0.060 |
Why?
|
| Mortality | 1 | 2017 | 2904 | 0.060 |
Why?
|
| Logistic Models | 2 | 2001 | 13266 | 0.060 |
Why?
|
| Patient Selection | 2 | 2014 | 4255 | 0.060 |
Why?
|
| Tetrachloroethylene | 1 | 2004 | 7 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 1984 | 134 | 0.060 |
Why?
|
| Drug Design | 1 | 2009 | 1042 | 0.060 |
Why?
|
| Heart Failure | 3 | 2017 | 11840 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12509 | 0.050 |
Why?
|
| Mathematics | 2 | 1994 | 696 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 1672 | 0.050 |
Why?
|
| Biological Assay | 1 | 2004 | 627 | 0.050 |
Why?
|
| Aged | 11 | 2018 | 171117 | 0.040 |
Why?
|
| Drug Therapy | 2 | 2013 | 504 | 0.040 |
Why?
|
| Stroke | 3 | 2018 | 9747 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 3646 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 4850 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 6309 | 0.030 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2017 | 89 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9373 | 0.030 |
Why?
|
| Schizophrenia | 2 | 2010 | 6972 | 0.030 |
Why?
|
| Classification | 1 | 1996 | 128 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2016 | 24282 | 0.030 |
Why?
|
| Female | 19 | 2018 | 396112 | 0.030 |
Why?
|
| Middle Aged | 12 | 2018 | 223009 | 0.030 |
Why?
|
| Genitalia | 1 | 1996 | 114 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1995 | 114 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5389 | 0.030 |
Why?
|
| Male | 15 | 2018 | 363698 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 6832 | 0.030 |
Why?
|
| Accident Prevention | 1 | 1994 | 76 | 0.030 |
Why?
|
| Carotenoids | 1 | 1996 | 619 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 1995 | 240 | 0.030 |
Why?
|
| Survival Rate | 2 | 2018 | 12795 | 0.030 |
Why?
|
| Sodium | 1 | 2017 | 1591 | 0.020 |
Why?
|
| Selection Bias | 1 | 1994 | 361 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 13451 | 0.020 |
Why?
|
| Hospitalization | 3 | 2016 | 10808 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 13462 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 1994 | 240 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2017 | 1591 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1472 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 909 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 2411 | 0.020 |
Why?
|
| Incidence | 2 | 2018 | 21480 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 5876 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 2108 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4908 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 1996 | 1014 | 0.020 |
Why?
|
| United States | 3 | 2018 | 72903 | 0.020 |
Why?
|
| Hypotension | 1 | 2015 | 885 | 0.020 |
Why?
|
| Analgesics | 1 | 1995 | 1060 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5526 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1441 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 4015 | 0.020 |
Why?
|
| Pregnancy | 3 | 2001 | 30260 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 1736 | 0.020 |
Why?
|
| Time Factors | 1 | 2008 | 40065 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 2247 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8529 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 697 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6499 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9591 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1996 | 4040 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1988 | 1326 | 0.010 |
Why?
|
| Infant | 2 | 2015 | 36386 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 978 | 0.010 |
Why?
|
| Drug Industry | 1 | 2009 | 791 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12056 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2015 | 5125 | 0.010 |
Why?
|
| Contraceptive Devices | 1 | 2001 | 25 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 86 | 0.010 |
Why?
|
| Cat Diseases | 1 | 2001 | 32 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1994 | 9649 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2009 | 2354 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 2000 | 39 | 0.010 |
Why?
|
| Toxicology | 1 | 2001 | 102 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2016 | 54802 | 0.010 |
Why?
|
| Cats | 1 | 2001 | 972 | 0.010 |
Why?
|
| Random Allocation | 2 | 2000 | 2395 | 0.010 |
Why?
|
| Eye Abnormalities | 1 | 2001 | 243 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15880 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1995 | 4416 | 0.010 |
Why?
|
| Animals | 4 | 2004 | 168764 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 74840 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2001 | 335 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 59489 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 2001 | 364 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1995 | 22223 | 0.010 |
Why?
|
| Corneal Transplantation | 1 | 2001 | 315 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 26346 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 744 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29922 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 2001 | 805 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 1316 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11868 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41649 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14652 | 0.010 |
Why?
|
| Adult | 3 | 2015 | 223044 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 20124 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 2531 | 0.010 |
Why?
|
| HIV Infections | 1 | 1995 | 17533 | 0.000 |
Why?
|
| Neoplasms | 1 | 1994 | 22340 | 0.000 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1988 | 540 | 0.000 |
Why?
|
| Rats | 1 | 2000 | 23707 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 7478 | 0.000 |
Why?
|
| Estrogens | 1 | 1988 | 1529 | 0.000 |
Why?
|
| Uterine Neoplasms | 1 | 1988 | 1421 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1981 | 13648 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 81819 | 0.000 |
Why?
|
| Adolescent | 1 | 2001 | 88835 | 0.000 |
Why?
|
| Smoking | 1 | 1988 | 9081 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1981 | 4044 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1981 | 6364 | 0.000 |
Why?
|